Physician profile
Steven Mitchell Marcet
NPI 1255300976
$2,296.03
in general payments reported to CMS, 2019-2025
16 companies · $548 in 2025
The $548 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.82 · 2022: $381 · 2023: $429 · 2024: $915 · 2025: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,891.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $634.03 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $325.19 | 2022-2025 | Dupixent, Libtayo |
| Incyte Corporation | $272.93 | 2022-2024 | Opzelura |
| Leo Pharma INC. | $209.31 | 2022-2025 | Adbry, Spevigo |
| Sun Pharmaceutical Industries INC. | $164.08 | 2022-2024 | Winlevi |
| Lilly USA, LLC | $132.10 | 2019-2024 | Taltz, Ebglyss |
| Janssen Biotech, INC. | $115.04 | 2023-2024 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $99.22 | 2024-2025 | Sotyktu |
| Amgen INC. | $75.43 | 2022-2025 | Otezla, Otezla |
| Genzyme Corporation | $68.29 | 2022-2023 | |
| Galderma Laboratories, L.P. | $54.00 | 2022-2025 | Nemluvio |
| Mayne Pharma Commercial LLC | $47.85 | 2023-2024 | |
| Ucb, INC. | $33.58 | 2024 | Bimzelx |
| Pfizer INC. | $30.33 | 2022-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.83 | 2023 | Siliq, Targretin |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.82 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Marcet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.